These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 23881527)

  • 1. Hexahydrocannabinol Pharmacology, Toxicology, and Analysis: The First Evidence for a Recent New Psychoactive Substance.
    Graziano S; Varì MR; Pichini S; Busardo FP; Cassano T; Di Trana A
    Curr Neuropharmacol; 2023; 21(12):2424-2430. PubMed ID: 37357519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond THC: The New Generation of Cannabinoid Designer Drugs.
    Fattore L; Fratta W
    Front Behav Neurosci; 2011; 5():60. PubMed ID: 22007163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. French medicine regulator bans two cannabinoid derivatives after reported side effects.
    Casassus B
    BMJ; 2024 Jun; 385():q1249. PubMed ID: 38843900
    [No Abstract]   [Full Text] [Related]  

  • 4. Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act.
    Kühnl R; Aydin D; Horn S; Olderbak S; Verthein U; Kraus L
    Harm Reduct J; 2022 Nov; 19(1):122. PubMed ID: 36329471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair Testing for Drugs of Abuse and New Psychoactive Substances in a High-Risk Population.
    Salomone A; Palamar JJ; Gerace E; Di Corcia D; Vincenti M
    J Anal Toxicol; 2017 Jun; 41(5):376-381. PubMed ID: 28334805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs of abuse: current perspectives on synthetic cannabinoids.
    Debruyne D; Le Boisselier R
    Subst Abuse Rehabil; 2015; 6():113-29. PubMed ID: 26543389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Chasing the high" - experiences of ethylphenidate as described on international internet forums.
    Soussan C; Kjellgren A
    Subst Abuse; 2015; 9():9-16. PubMed ID: 25788832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harm reduction and knowledge exchange-a qualitative analysis of drug-related Internet discussion forums.
    Soussan C; Kjellgren A
    Harm Reduct J; 2014 Sep; 11():25. PubMed ID: 25200686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.
    Krasowski MD; Ekins S
    J Cheminform; 2014; 6():22. PubMed ID: 24851137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
    Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
    Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic cannabinoid receptor agonists: classification and nomenclature.
    Potts AJ; Cano C; Thomas SHL; Hill SL
    Clin Toxicol (Phila); 2020 Feb; 58(2):82-98. PubMed ID: 31524007
    [No Abstract]   [Full Text] [Related]  

  • 12. Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan.
    Kikura-Hanajiri R; Kawamura NU; Goda Y
    Drug Test Anal; 2014; 6(7-8):832-9. PubMed ID: 24573957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legal controls on cannabimimetics: an international dilemma?
    King LA
    Drug Test Anal; 2014; 6(1-2):80-7. PubMed ID: 23881527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'.
    Dargan PI; Hudson S; Ramsey J; Wood DM
    Int J Drug Policy; 2011 Jul; 22(4):274-7. PubMed ID: 21482092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.